文库 R_医药、卫生 骨科

VTE_full_guideline.pdf

骨科指南与进展2011年-2013年 PDF   865页   下载0   2025-02-28   浏览5   收藏0   点赞0   评分-   1532232字   10积分
温馨提示:当前文档最多只能预览 10 页,若文档总页数超出了 10 页,请下载原文档以浏览全部内容。
VTE_full_guideline.pdf 第1页
VTE_full_guideline.pdf 第2页
VTE_full_guideline.pdf 第3页
VTE_full_guideline.pdf 第4页
VTE_full_guideline.pdf 第5页
VTE_full_guideline.pdf 第6页
VTE_full_guideline.pdf 第7页
VTE_full_guideline.pdf 第8页
VTE_full_guideline.pdf 第9页
VTE_full_guideline.pdf 第10页
剩余855页未读, 下载浏览全部
AAOS Clincal Practice Guidelines Unit i v1.0_ 092311 PREVENTING VENOUS THROMBOEMBOLIC DISEASE IN PATIENTS UNDERGOING ELECTIVE HIP AND KNEE ARTHROPLASTY EVIDENCE-BASED GUIDELINE AND EVIDENCE REPORT AAOS Clincal Practice Guidelines Unit ii v1.0_ 092311 Disclaimer This clinical guideline was developed by an AAOS physician volunteer Work Group and experts in systematic reviews. It is provided as an educational tool based on an assessment of the current scientific and clinical information and accepted approaches to treatment. The recommendations in this guideline are not intended to be a fixed protocol as some patients may require more or less treatment or different means of diagnosis. Patients seen in clinical practice may not be the same as those found in a clinical trial. Patient care and treatment should always be based on a clinician’s independent medical judgment given the individual clinical circumstances. Disclosure Requirement In accordance with AAOS policy, all individuals whose names appear as authors or contributors to this clinical practice guideline filed a disclosure statement as part of the submission process. All panel members provided full disclosure of potential conflicts of interest prior to beginning work on the recommendations contained within this clinical practice guideline. Funding Source The American Academy of Orthopaedic Surgeons exclusively funded this clinical practice guideline. The Academy received no funding from outside commercial sources to support the development of this document. FDA Clearance Some drugs or medical devices referenced or described in this clinical practice guideline may not have been cleared by the Food and Drug Administration (FDA) or may have been cleared for a specific use only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice. Copyright All rights reserved
VTE_full_guideline.pdf